Filing Details
- Accession Number:
- 0001562180-23-008172
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-12-06 17:20:23
- Reporting Period:
- 2023-12-04
- Accepted Time:
- 2023-12-06 17:20:23
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1314102 | Eyepoint Pharmaceuticals Inc. | EYPT | Laboratory Analytical Instruments (3826) | 262774444 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1904458 | Craig Michael Pine | 480 Pleasant St, Ste A210 Watertown MA 02472 | Chief Corp Dev.&Strat. Officer | No | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2023-12-04 | 45,000 | $12.62 | 50,343 | No | 4 | M | Direct | |
Common Stock | Disposition | 2023-12-04 | 45,000 | $22.00 | 5,343 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (Right to Buy) | Disposition | 2023-12-04 | 45,000 | $0.00 | 45,000 | $12.62 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
55,000 | 2032-01-10 | No | 4 | M | Direct |
Footnotes
- Includes 2,159 shares acquired on January 31, 2023 and 2,184 shares acquired on July 31,2023 pursuant to EyePoint's 2019 Employee Stock Purchase Plan.
- The option to purchase will vest and become exercisable as follows: 25% at January 10th, 2023 and the remainder ratably, on a monthly basis, over the remaining three years.